We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 20 of 218 for:    "Pneumonia, Ventilator-Associated"

Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00935285
Recruitment Status : Unknown
Verified July 2009 by University of Thessaly.
Recruitment status was:  Active, not recruiting
First Posted : July 9, 2009
Last Update Posted : July 9, 2009
Information provided by:
University of Thessaly

Brief Summary:
Ventilator-associated pneumonia (VAP) is very common in the intensive care unit (ICU), affecting 9 to 40% of ICU patients and mortality rates range from 20 to 50% and may reach more than 70% when the infection is caused by multi-resistant and invasive pathogens. The most common pathogens that cause VAP are the Gram(-) bacteria. Findings indicate that TLRs serves as an important signal in the generation of protective innate responses to bacterial pathogens of the lung and that is required for effective innate immune responses against Gram-negative bacterial pathogens. There is genetic evidence that mutations in TLRs increase the risk of developing nosocomial infections. Understanding the TLR system should offer invaluable opportunity for manipulating host immune responses.

Condition or disease
Ventilator-Associated Pneumonia

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immune Response in Patients Who Develop Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) and the Role of Toll-Like Receptors(TLR2,TLR4,TLR9).
Study Start Date : July 2009
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   14 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will include ICU patients who receive mechanical ventilation <48h and have no history of ΑRDS or other respiratory disease.

Inclusion Criteria:

  • Presence in intensive care unit receive mechanical ventilation <48h have no history of ΑRDS or other respiratory disease

Exclusion Criteria:

  • Length of stay <24 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00935285

Larisa, Mezourlo, Greece, 41335
Sponsors and Collaborators
University of Thessaly
Principal Investigator: Sofia Sarafi RN MSc, ICU University Hospital Larisa

ClinicalTrials.gov Identifier: NCT00935285     History of Changes
Other Study ID Numbers: 1692UT
First Posted: July 9, 2009    Key Record Dates
Last Update Posted: July 9, 2009
Last Verified: July 2009

Keywords provided by University of Thessaly:
Ventilator-associated pneumonia (VAP)
Intensive care unit (ICU)
Toll-like receptors

Additional relevant MeSH terms:
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Ventilator-Induced Lung Injury
Lung Injury